Industry Research Reports

Home > Reports > Pharma & Healthcare > Global Omalizumab Biosimilars Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032

Global Omalizumab Biosimilars Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032

Industry: Pharma & Healthcare

Published Date: 2026-04-16

Pages: 142 Pages

Report ld: 6456593

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Omalizumab Biosimilars Market Size(US$)

CAGR 2026-2032

11.2%

Market Size,2032

USD 598

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 315 million

Market Forecast in 2032(Value)

US$ 598 million

CAGR

11.2%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Omalizumab Biosimilars market size was US$ 290 million in 2025 and is forecast to reach a readjusted size of US$ 598 million by 2032 with a CAGR of 11.2% during the forecast period 2026-2032.

In 2025, global Omalizumab Biosimilars production reached approximately 909 k doses, with an average global market price of around US$ 319 per dose. Gross margin is about 43%. The cost is 182 usd, the production is 1200 k doses. Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.

The market is entering a rapid commercialization stage

As the first omalizumab biosimilars gain approval in major markets such as Europe and the United States, the market is shifting from development and regulatory preparation to commercialization and competition. More biosimilar manufacturers are expected to enter the market, accelerating adoption and increasing competition.

Price competition will become increasingly important

As more omalizumab biosimilars are launched, price competition is expected to intensify. Lower treatment costs will improve patient access and encourage hospitals, insurers, and healthcare systems to promote biosimilar substitution over the original branded drug.

Interchangeability will become a key competitive advantage

In the United States, interchangeability status is likely to become an important factor influencing market share. Biosimilars with interchangeable designation may gain stronger acceptance from pharmacies, payers, and physicians because they can be substituted more easily for the original product.

More dosage forms and specifications will be introduced

Manufacturers are expected to launch additional dosage strengths, pre-filled syringes, auto-injectors, and patient-friendly packaging formats. Competition will increasingly depend on product portfolios, ease of administration, and compatibility with existing treatment practices.

Expansion of indications will increase long-term market potential

As the original omalizumab product continues to gain approvals for new indications such as food allergy, nasal polyps, and other IgE-mediated diseases, biosimilars are also expected to benefit from a larger addressable market in the future.

The global Omalizumab Biosimilars market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2021-2032.

MARKET SEGMENTATION

By Company

Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
CuraTeQ
Celltrion Healthcare
Alvotech
BiosanaPharma
Mabpharm
CSPC Pharmaceutical Group
Biomabs
HisunPharm

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

150 mg/mL
75 mg/0.5 mL

Segment by Application

Persistent Asthma
Nasal Polyps
Chronic Idiopathic Urticaria

Segment by Category

For Adults
For Teenagers
For Children

Segment by Division

Every 2 Weeks
Every 4 Weeks
Individualized Dosing Regimen

biaoTi CHAPTER OUTLINE

Chapter 1: Report scope, segment-level executive summary (by Type, by Application) and market evolution across the short, mid and long term

Chapter 2: Quantitative analysis of Omalizumab Biosimilars sales and revenue at global, regional, and country levels, highlighting market size and growth potential by region

Chapter 3: Competitive landscape of Omalizumab Biosimilars manufacturers (sales, revenue, pricing, market share, industry rankings, and M&A / expansion plans)

Chapter 4: by Type-based segmentation analysis (sales, revenue, pricing, and growth potential) to identify blue-ocean product segments

Chapter 5: by Application-based segmentation analysis (sales, revenue, pricing, and growth potential) to uncover high-value downstream markets

Chapter 6: Regional breakdown by company, customer, by Type and by Application (sales, revenue, and pricing for each segment)

Chapter 7: Key manufacturer profiles –company overview, Omalizumab Biosimilars product descriptions and specifications, revenue, gross margins, and recent developments

Chapter 8: Industry chain analysis – upstream raw materials, manufacturing links, and downstream application sectors

Chapter 9: Sales channels and distributor analysis – routes to market and key customer interfaces

Chapter 10: Market dynamics – trends, drivers, restraints, risks for manufacturers, and the impact of relevant industry policies

Chapter 11: Key findings, main takeaways, and overall conclusions of the report.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Omalizumab Biosimilars value chain, addressing:

- Market entry risks/opportunities by region

- Product mix optimization based on local practices

- Competitor tactics in fragmented vs. consolidated markets

biaoTi QYRESEARCH'S STRENGTHS

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Omalizumab Biosimilars Product Scope

1.2 Omalizumab Biosimilars by Type

1.2.1 Global Omalizumab Biosimilars Sales by Type (2021, 2025 & 2032)

1.2.2 150 mg/mL

1.2.3 75 mg/0.5 mL

1.3 Omalizumab Biosimilars by Application

1.3.1 Global Omalizumab Biosimilars Sales Comparison by Application (2021, 2025 & 2032)

1.3.2 Persistent Asthma

1.3.3 Nasal Polyps

1.3.4 Chronic Idiopathic Urticaria

1.4 Global Omalizumab Biosimilars Market Estimates and Forecasts (2021-2032)

1.4.1 Global Omalizumab Biosimilars Market Size (Value) and Growth Rate (2021-2032)

1.4.2 Global Omalizumab Biosimilars Market Size (Volume) and Growth Rate (2021-2032)

1.4.3 Global Omalizumab Biosimilars Price Trends (2021-2032)

1.5 Assumptions and Limitations

2 Market Size and Prospects by Region

2.1 Global Omalizumab Biosimilars Market Size by Region: 2021 VS 2025 VS 2032

2.2 Global Omalizumab Biosimilars Historical Market Scenario by Region (2021-2026)

2.2.1 Global Omalizumab Biosimilars Sales Market Share by Region (2021-2026)

2.2.2 Global Omalizumab Biosimilars Revenue Market Share by Region (2021-2026)

2.3 Global Omalizumab Biosimilars Market Estimates and Forecasts by Region (2027-2032)

2.3.1 Global Omalizumab Biosimilars Sales Estimates and Forecasts by Region (2027-2032)

2.3.2 Global Omalizumab Biosimilars Revenue Forecast by Region (2027-2032)

2.4 Major Regions and Emerging Market Analysis

2.4.1 North America Omalizumab Biosimilars Market Size and Prospects (2021-2032)

2.4.2 Europe Omalizumab Biosimilars Market Size and Prospects (2021-2032)

2.4.3 China Omalizumab Biosimilars Market Size and Prospects (2021-2032)

2.4.4 Japan Omalizumab Biosimilars Market Size and Prospects (2021-2032)

3 Global Market Size by Type

3.1 Global Omalizumab Biosimilars Historical Market Review by Type (2021-2026)

3.1.1 Global Omalizumab Biosimilars Sales by Type (2021-2026)

3.1.2 Global Omalizumab Biosimilars Revenue by Type (2021-2026)

3.1.3 Global Omalizumab Biosimilars Average Price by Type (2021-2026)

3.2 Global Omalizumab Biosimilars Market Estimates and Forecasts by Type (2027-2032)

3.2.1 Global Omalizumab Biosimilars Sales Forecast by Type (2027-2032)

3.2.2 Global Omalizumab Biosimilars Revenue Forecast by Type (2027-2032)

3.2.3 Global Omalizumab Biosimilars Price Forecast by Type (2027-2032)

3.3 Representative Players for Different Types of Omalizumab Biosimilars

4 Global Market Size by Application

4.1 Global Omalizumab Biosimilars Historical Market Review by Application (2021-2026)

4.1.1 Global Omalizumab Biosimilars Sales by Application (2021-2026)

4.1.2 Global Omalizumab Biosimilars Revenue by Application (2021-2026)

4.1.3 Global Omalizumab Biosimilars Average Price by Application (2021-2026)

4.2 Global Omalizumab Biosimilars Market Estimates and Forecasts by Application (2027-2032)

4.2.1 Global Omalizumab Biosimilars Sales Forecast by Application (2027-2032)

4.2.2 Global Omalizumab Biosimilars Revenue Forecast by Application (2027-2032)

4.2.3 Global Omalizumab Biosimilars Price Forecast by Application (2027-2032)

4.3 New Sources of Growth in Omalizumab Biosimilars Applications

5 Competition Landscape by Players

5.1 Global Omalizumab Biosimilars Sales by Player (2021-2026)

5.2 Global Top Omalizumab Biosimilars Players by Revenue (2021-2026)

5.3 Global Omalizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3), based on Omalizumab Biosimilars revenue as of 2025

5.4 Global Omalizumab Biosimilars Average Price by Company (2021-2026)

5.5 Global Key Manufacturers of Omalizumab Biosimilars, Manufacturing Sites & Headquarters

5.6 Global Key Manufacturers of Omalizumab Biosimilars, Product Type & Application

5.7 Global Key Manufacturers of Omalizumab Biosimilars, Date of Entry into This Industry

5.8 Manufacturers Mergers & Acquisitions, Expansion Plans

6 Regional Analysis

6.1 North America Market: Players, Segments, Downstream and Major Customers

6.1.1 North America Omalizumab Biosimilars Sales by Company

6.1.1.1 North America Omalizumab Biosimilars Sales by Company (2021-2026)

6.1.1.2 North America Omalizumab Biosimilars Revenue by Company (2021-2026)

6.1.2 North America Omalizumab Biosimilars Sales Breakdown by Type (2021-2026)

6.1.3 North America Omalizumab Biosimilars Sales Breakdown by Application (2021-2026)

6.1.4 North America Omalizumab Biosimilars Major Customers

6.1.5 North America Market Trends and Opportunities

6.2 Europe Market: Players, Segments, Downstream and Major Customers

6.2.1 Europe Omalizumab Biosimilars Sales by Company

6.2.1.1 Europe Omalizumab Biosimilars Sales by Company (2021-2026)

6.2.1.2 Europe Omalizumab Biosimilars Revenue by Company (2021-2026)

6.2.2 Europe Omalizumab Biosimilars Sales Breakdown by Type (2021-2026)

6.2.3 Europe Omalizumab Biosimilars Sales Breakdown by Application (2021-2026)

6.2.4 Europe Omalizumab Biosimilars Major Customers

6.2.5 Europe Market Trends and Opportunities

6.3 China Market: Players, Segments, Downstream and Major Customers

6.3.1 China Omalizumab Biosimilars Sales by Company

6.3.1.1 China Omalizumab Biosimilars Sales by Company (2021-2026)

6.3.1.2 China Omalizumab Biosimilars Revenue by Company (2021-2026)

6.3.2 China Omalizumab Biosimilars Sales Breakdown by Type (2021-2026)

6.3.3 China Omalizumab Biosimilars Sales Breakdown by Application (2021-2026)

6.3.4 China Omalizumab Biosimilars Major Customers

6.3.5 China Market Trends and Opportunities

6.4 Japan Market: Players, Segments, Downstream and Major Customers

6.4.1 Japan Omalizumab Biosimilars Sales by Company

6.4.1.1 Japan Omalizumab Biosimilars Sales by Company (2021-2026)

6.4.1.2 Japan Omalizumab Biosimilars Revenue by Company (2021-2026)

6.4.2 Japan Omalizumab Biosimilars Sales Breakdown by Type (2021-2026)

6.4.3 Japan Omalizumab Biosimilars Sales Breakdown by Application (2021-2026)

6.4.4 Japan Omalizumab Biosimilars Major Customers

6.4.5 Japan Market Trends and Opportunities

7 Company Profiles and Key Figures

7.1 Roche

7.1.1 Roche Company Information

7.1.2 Roche Business Overview

7.1.3 Roche Omalizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)

7.1.4 Roche Omalizumab Biosimilars Products Offered

7.1.5 Roche Recent Development

7.2 Novartis

7.2.1 Novartis Company Information

7.2.2 Novartis Business Overview

7.2.3 Novartis Omalizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)

7.2.4 Novartis Omalizumab Biosimilars Products Offered

7.2.5 Novartis Recent Development

7.3 Glenmark Pharmaceuticals

7.3.1 Glenmark Pharmaceuticals Company Information

7.3.2 Glenmark Pharmaceuticals Business Overview

7.3.3 Glenmark Pharmaceuticals Omalizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)

7.3.4 Glenmark Pharmaceuticals Omalizumab Biosimilars Products Offered

7.3.5 Glenmark Pharmaceuticals Recent Development

7.4 Selexis

7.4.1 Selexis Company Information

7.4.2 Selexis Business Overview

7.4.3 Selexis Omalizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)

7.4.4 Selexis Omalizumab Biosimilars Products Offered

7.4.5 Selexis Recent Development

7.5 Generium

7.5.1 Generium Company Information

7.5.2 Generium Business Overview

7.5.3 Generium Omalizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)

7.5.4 Generium Omalizumab Biosimilars Products Offered

7.5.5 Generium Recent Development

7.6 CuraTeQ

7.6.1 CuraTeQ Company Information

7.6.2 CuraTeQ Business Overview

7.6.3 CuraTeQ Omalizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)

7.6.4 CuraTeQ Omalizumab Biosimilars Products Offered

7.6.5 CuraTeQ Recent Development

7.7 Celltrion Healthcare

7.7.1 Celltrion Healthcare Company Information

7.7.2 Celltrion Healthcare Business Overview

7.7.3 Celltrion Healthcare Omalizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)

7.7.4 Celltrion Healthcare Omalizumab Biosimilars Products Offered

7.7.5 Celltrion Healthcare Recent Development

7.8 Alvotech

7.8.1 Alvotech Company Information

7.8.2 Alvotech Business Overview

7.8.3 Alvotech Omalizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)

7.8.4 Alvotech Omalizumab Biosimilars Products Offered

7.8.5 Alvotech Recent Development

7.9 BiosanaPharma

7.9.1 BiosanaPharma Company Information

7.9.2 BiosanaPharma Business Overview

7.9.3 BiosanaPharma Omalizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)

7.9.4 BiosanaPharma Omalizumab Biosimilars Products Offered

7.9.5 BiosanaPharma Recent Development

7.10 Mabpharm

7.10.1 Mabpharm Company Information

7.10.2 Mabpharm Business Overview

7.10.3 Mabpharm Omalizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)

7.10.4 Mabpharm Omalizumab Biosimilars Products Offered

7.10.5 Mabpharm Recent Development

7.11 CSPC Pharmaceutical Group

7.11.1 CSPC Pharmaceutical Group Company Information

7.11.2 CSPC Pharmaceutical Group Business Overview

7.11.3 CSPC Pharmaceutical Group Omalizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)

7.11.4 CSPC Pharmaceutical Group Omalizumab Biosimilars Products Offered

7.11.5 CSPC Pharmaceutical Group Recent Development

7.12 Biomabs

7.12.1 Biomabs Company Information

7.12.2 Biomabs Business Overview

7.12.3 Biomabs Omalizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)

7.12.4 Biomabs Omalizumab Biosimilars Products Offered

7.12.5 Biomabs Recent Development

7.13 HisunPharm

7.13.1 HisunPharm Company Information

7.13.2 HisunPharm Business Overview

7.13.3 HisunPharm Omalizumab Biosimilars Sales, Revenue and Gross Margin (2021-2026)

7.13.4 HisunPharm Omalizumab Biosimilars Products Offered

7.13.5 HisunPharm Recent Development

8 Omalizumab Biosimilars Manufacturing Cost Analysis

8.1 Omalizumab Biosimilars Key Raw Materials Analysis

8.1.1 Key Raw Materials

8.1.2 Key Suppliers of Raw Materials

8.2 Manufacturing Cost Structure

8.3 Manufacturing Process Analysis of Omalizumab Biosimilars

8.4 Omalizumab Biosimilars Industrial Chain Analysis

9 Marketing Channels, Distributors and Customers

9.1 Marketing Channels

9.2 Omalizumab Biosimilars Distributors List

9.3 Omalizumab Biosimilars Customers

10 Omalizumab Biosimilars Market Dynamics

10.1 Omalizumab Biosimilars Industry Trends

10.2 Omalizumab Biosimilars Market Drivers

10.3 Omalizumab Biosimilars Market Challenges

10.4 Omalizumab Biosimilars Market Restraints

11 Research Findings and Conclusion

12 Appendix

12.1 Research Methodology

12.1.1 Methodology/Research Approach

12.1.1.1 Research Programs/Design

12.1.1.2 Market Size Estimation

12.1.1.3 Market Breakdown and Data Triangulation

12.1.2 Data Source

12.1.2.1 Secondary Sources

12.1.2.2 Primary Sources

12.2 Author Details

12.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Omalizumab Biosimilars Sales (US$ Million) Growth Rate by Type (2021, 2025 & 2032)

Table 2. Global Omalizumab Biosimilars Sales (US$ Million) Comparison by Application (2021, 2025 & 2032)

Table 3. Global Market Omalizumab Biosimilars Market Size (US$ Million) by Region:2021 VS 2025 VS 2032

Table 4. Global Omalizumab Biosimilars Sales (K Dose) by Region (2021-2026)

Table 5. Global Omalizumab Biosimilars Sales Market Share by Region (2021-2026)

Table 6. Global Omalizumab Biosimilars Revenue (US$ Million) Market Share by Region (2021-2026)

Table 7. Global Omalizumab Biosimilars Revenue Share by Region (2021-2026)

Table 8. Global Omalizumab Biosimilars Sales (K Dose) Forecast by Region (2027-2032)

Table 9. Global Omalizumab Biosimilars Sales Market Share Forecast by Region (2027-2032)

Table 10. Global Omalizumab Biosimilars Revenue (US$ Million) Forecast by Region (2027-2032)

Table 11. Global Omalizumab Biosimilars Revenue Share Forecast by Region (2027-2032)

Table 12. Global Omalizumab Biosimilars Sales by Type (K Dose) & (2021-2026)

Table 13. Global Omalizumab Biosimilars Sales Share by Type (2021-2026)

Table 14. Global Omalizumab Biosimilars Revenue by Type (US$ Million) & (2021-2026)

Table 15. Global Omalizumab Biosimilars Average Price by Type (US$/Dose) & (2021-2026)

Table 16. Global Omalizumab Biosimilars Sales by Type (K Dose) & (2027-2032)

Table 17. Global Omalizumab Biosimilars Revenue by Type (US$ Million) & (2027-2032)

Table 18. Global Omalizumab Biosimilars Average Price by Type (US$/Dose) & (2027-2032)

Table 19. Representative Players of Each Type

Table 20. Global Omalizumab Biosimilars Sales by Application (K Dose) & (2021-2026)

Table 21. Global Omalizumab Biosimilars Sales Share by Application (2021-2026)

Table 22. Global Omalizumab Biosimilars Revenue by Application (US$ Million) & (2021-2026)

Table 23. Global Omalizumab Biosimilars Average Price by Application (US$/Dose) & (2021-2026)

Table 24. Global Omalizumab Biosimilars Sales by Application (K Dose) & (2027-2032)

Table 25. Global Omalizumab Biosimilars Revenue Market Share by Application (US$ Million) & (2027-2032)

Table 26. Global Omalizumab Biosimilars Average Price by Application (US$/Dose) & (2027-2032)

Table 27. New Sources of Growth in Omalizumab Biosimilars Applications

Table 28. Global Omalizumab Biosimilars Sales by Company (K Dose) & (2021-2026)

Table 29. Global Omalizumab Biosimilars Sales Share by Company (2021-2026)

Table 30. Global Omalizumab Biosimilars Revenue by Company (US$ Million) & (2021-2026)

Table 31. Global Omalizumab Biosimilars Revenue Share by Company (2021-2026)

Table 32. Global Omalizumab Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Omalizumab Biosimilars as of 2025)

Table 33. Global Market Omalizumab Biosimilars Average Price by Company (US$/Dose) & (2021-2026)

Table 34. Global Key Manufacturers of Omalizumab Biosimilars, Manufacturing Sites & Headquarters

Table 35. Global Key Manufacturers of Omalizumab Biosimilars, Product Type & Application

Table 36. Global Key Manufacturers of Omalizumab Biosimilars, Date of Entry into This Industry

Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 38. North America Omalizumab Biosimilars Sales by Company (2021-2026) & (K Dose)

Table 39. North America Omalizumab Biosimilars Sales Market Share by Company (2021-2026)

Table 40. North America Omalizumab Biosimilars Revenue by Company (2021-2026) & (US$ Million)

Table 41. North America Omalizumab Biosimilars Revenue Market Share by Company (2021-2026)

Table 42. North America Omalizumab Biosimilars Sales by Type (2021-2026) & (K Dose)

Table 43. North America Omalizumab Biosimilars Sales Market Share by Type (2021-2026)

Table 44. North America Omalizumab Biosimilars Sales by Application (2021-2026) & (K Dose)

Table 45. North America Omalizumab Biosimilars Sales Market Share by Application (2021-2026)

Table 46. Europe Omalizumab Biosimilars Sales by Company (2021-2026) & (K Dose)

Table 47. Europe Omalizumab Biosimilars Sales Market Share by Company (2021-2026)

Table 48. Europe Omalizumab Biosimilars Revenue by Company (2021-2026) & (US$ Million)

Table 49. Europe Omalizumab Biosimilars Revenue Market Share by Company (2021-2026)

Table 50. Europe Omalizumab Biosimilars Sales by Type (2021-2026) & (K Dose)

Table 51. Europe Omalizumab Biosimilars Sales Market Share by Type (2021-2026)

Table 52. Europe Omalizumab Biosimilars Sales by Application (2021-2026) & (K Dose)

Table 53. Europe Omalizumab Biosimilars Sales Market Share by Application (2021-2026)

Table 54. China Omalizumab Biosimilars Sales by Company (2021-2026) & (K Dose)

Table 55. China Omalizumab Biosimilars Sales Market Share by Company (2021-2026)

Table 56. China Omalizumab Biosimilars Revenue by Company (2021-2026) & (US$ Million)

Table 57. China Omalizumab Biosimilars Revenue Market Share by Company (2021-2026)

Table 58. China Omalizumab Biosimilars Sales by Type (2021-2026) & (K Dose)

Table 59. China Omalizumab Biosimilars Sales Market Share by Type (2021-2026)

Table 60. China Omalizumab Biosimilars Sales by Application (2021-2026) & (K Dose)

Table 61. China Omalizumab Biosimilars Sales Market Share by Application (2021-2026)

Table 62. Japan Omalizumab Biosimilars Sales by Company (2021-2026) & (K Dose)

Table 63. Japan Omalizumab Biosimilars Sales Market Share by Company (2021-2026)

Table 64. Japan Omalizumab Biosimilars Revenue by Company (2021-2026) & (US$ Million)

Table 65. Japan Omalizumab Biosimilars Revenue Market Share by Company (2021-2026)

Table 66. Japan Omalizumab Biosimilars Sales by Type (2021-2026) & (K Dose)

Table 67. Japan Omalizumab Biosimilars Sales Market Share by Type (2021-2026)

Table 68. Japan Omalizumab Biosimilars Sales by Application (2021-2026) & (K Dose)

Table 69. Japan Omalizumab Biosimilars Sales Market Share by Application (2021-2026)

Table 70. Roche Company Information

Table 71. Roche Description and Business Overview

Table 72. Roche Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 73. Roche Omalizumab Biosimilars Product

Table 74. Roche Recent Development

Table 75. Novartis Company Information

Table 76. Novartis Description and Business Overview

Table 77. Novartis Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 78. Novartis Omalizumab Biosimilars Product

Table 79. Novartis Recent Development

Table 80. Glenmark Pharmaceuticals Company Information

Table 81. Glenmark Pharmaceuticals Description and Business Overview

Table 82. Glenmark Pharmaceuticals Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 83. Glenmark Pharmaceuticals Omalizumab Biosimilars Product

Table 84. Glenmark Pharmaceuticals Recent Development

Table 85. Selexis Company Information

Table 86. Selexis Description and Business Overview

Table 87. Selexis Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 88. Selexis Omalizumab Biosimilars Product

Table 89. Selexis Recent Development

Table 90. Generium Company Information

Table 91. Generium Description and Business Overview

Table 92. Generium Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 93. Generium Omalizumab Biosimilars Product

Table 94. Generium Recent Development

Table 95. CuraTeQ Company Information

Table 96. CuraTeQ Description and Business Overview

Table 97. CuraTeQ Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 98. CuraTeQ Omalizumab Biosimilars Product

Table 99. CuraTeQ Recent Development

Table 100. Celltrion Healthcare Company Information

Table 101. Celltrion Healthcare Description and Business Overview

Table 102. Celltrion Healthcare Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 103. Celltrion Healthcare Omalizumab Biosimilars Product

Table 104. Celltrion Healthcare Recent Development

Table 105. Alvotech Company Information

Table 106. Alvotech Description and Business Overview

Table 107. Alvotech Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 108. Alvotech Omalizumab Biosimilars Product

Table 109. Alvotech Recent Development

Table 110. BiosanaPharma Company Information

Table 111. BiosanaPharma Description and Business Overview

Table 112. BiosanaPharma Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 113. BiosanaPharma Omalizumab Biosimilars Product

Table 114. BiosanaPharma Recent Development

Table 115. Mabpharm Company Information

Table 116. Mabpharm Description and Business Overview

Table 117. Mabpharm Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 118. Mabpharm Omalizumab Biosimilars Product

Table 119. Mabpharm Recent Development

Table 120. CSPC Pharmaceutical Group Company Information

Table 121. CSPC Pharmaceutical Group Description and Business Overview

Table 122. CSPC Pharmaceutical Group Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 123. CSPC Pharmaceutical Group Omalizumab Biosimilars Product

Table 124. CSPC Pharmaceutical Group Recent Development

Table 125. Biomabs Company Information

Table 126. Biomabs Description and Business Overview

Table 127. Biomabs Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 128. Biomabs Omalizumab Biosimilars Product

Table 129. Biomabs Recent Development

Table 130. HisunPharm Company Information

Table 131. HisunPharm Description and Business Overview

Table 132. HisunPharm Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 133. HisunPharm Omalizumab Biosimilars Product

Table 134. HisunPharm Recent Development

Table 135. Production Base and Market Concentration Rate of Raw Material

Table 136. Key Suppliers of Raw Materials

Table 137. Omalizumab Biosimilars Distributors List

Table 138. Omalizumab Biosimilars Customers List

Table 139. Omalizumab Biosimilars Market Trends

Table 140. Omalizumab Biosimilars Market Drivers

Table 141. Omalizumab Biosimilars Market Challenges

Table 142. Omalizumab Biosimilars Market Restraints

Table 143. Research Programs/Design for This Report

Table 144. Key Data Information from Secondary Sources

Table 145. Key Data Information from Primary Sources

List of Figures

Figure 1. Omalizumab Biosimilars Product Picture

Figure 2. Global Omalizumab Biosimilars Sales (US$ Million) by Type (2021, 2025 & 2032)

Figure 3. Global Omalizumab Biosimilars Sales Market Share by Type in 2025 & 2032

Figure 4. 150 mg/mL Product Picture

Figure 5. 75 mg/0.5 mL Product Picture

Figure 6. Global Omalizumab Biosimilars Sales (US$ Million) by Application (2021, 2025 & 2032)

Figure 7. Global Omalizumab Biosimilars Sales Market Share by Application in 2025 & 2032

Figure 8. Persistent Asthma Examples

Figure 9. Nasal Polyps Examples

Figure 10. Chronic Idiopathic Urticaria Examples

Figure 11. Global Omalizumab Biosimilars Sales, (US$ Million), 2021 VS 2025 VS 2032

Figure 12. Global Omalizumab Biosimilars Sales Growth Rate (2021-2032) & (US$ Million)

Figure 13. Global Omalizumab Biosimilars Sales (K Dose) Growth Rate (2021-2032)

Figure 14. Global Omalizumab Biosimilars Price Trends Growth Rate (2021-2032) & (US$/Dose)

Figure 15. Omalizumab Biosimilars Report Years Considered

Figure 16. Global Market Omalizumab Biosimilars Market Size (US$ Million) by Region:2021 VS 2025 VS 2032

Figure 17. Global Omalizumab Biosimilars Revenue Market Share by Region: 2021 VS 2025

Figure 18. North America Omalizumab Biosimilars Revenue (US$ Million) Growth Rate (2021-2032)

Figure 19. North America Omalizumab Biosimilars Sales (K Dose) Growth Rate (2021-2032)

Figure 20. Europe Omalizumab Biosimilars Revenue (US$ Million) Growth Rate (2021-2032)

Figure 21. Europe Omalizumab Biosimilars Sales (K Dose) Growth Rate (2021-2032)

Figure 22. China Omalizumab Biosimilars Revenue (US$ Million) Growth Rate (2021-2032)

Figure 23. China Omalizumab Biosimilars Sales (K Dose) Growth Rate (2021-2032)

Figure 24. Japan Omalizumab Biosimilars Revenue (US$ Million) Growth Rate (2021-2032)

Figure 25. Japan Omalizumab Biosimilars Sales (K Dose) Growth Rate (2021-2032)

Figure 26. Global Omalizumab Biosimilars Revenue Share by Type (2021-2026)

Figure 27. Global Omalizumab Biosimilars Sales Share by Type (2027-2032)

Figure 28. Global Omalizumab Biosimilars Revenue Share by Type (2027-2032)

Figure 29. Global Omalizumab Biosimilars Revenue Share by Application (2021-2026)

Figure 30. Global Omalizumab Biosimilars Revenue Market Share by Application in 2021 & 2025

Figure 31. Global Omalizumab Biosimilars Sales Share by Application (2027-2032)

Figure 32. Global Omalizumab Biosimilars Revenue Share by Application (2027-2032)

Figure 33. Global Omalizumab Biosimilars Sales Share by Company (2025)

Figure 34. Global Omalizumab Biosimilars Revenue Share by Company (2025)

Figure 35. Global 5 Largest Omalizumab Biosimilars Players Market Share by Revenue in Omalizumab Biosimilars: 2021 & 2025

Figure 36. Omalizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025

Figure 37. Manufacturing Cost Structure of Omalizumab Biosimilars

Figure 38. Manufacturing Process Analysis of Omalizumab Biosimilars

Figure 39. Omalizumab Biosimilars Industrial Chain

Figure 40. Channels of Distribution (Direct Vs Distribution)

Figure 41. Distributors Profiles

Figure 42. Bottom-up and Top-down Approaches for This Report

Figure 43. Data Triangulation

Figure 44. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What was the global market size of Omalizumab Biosimilars in 2032? zhanKai

The global market size of Omalizumab Biosimilars in 2032 was 598 Million USD.

Which region is expected to have the highest market share? shouQi

What was the global market size of Omalizumab Biosimilars in 2026? shouQi

Which companies rank high in the global Omalizumab Biosimilars market? shouQi

What is the annual compound growth rate of the global Omalizumab Biosimilars market size from 2026 to 2032? shouQi

Related Reports

Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Omalizumab Biosimilars was estimated to be worth US$ 290 million in 2025 and is projected to reach US$ 598 million, growing at a CAGR of 11.2% from 2026 to 2032.
Published Date: 2026-04-16
Pages: 139
USD 3950.00
(Single User License)
Global Omalizumab Biosimilars Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Omalizumab Biosimilars market is projected to grow from US$ 290 million in 2025 to US$ 598 million by 2032, at a CAGR of 11.2% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-04-16
Pages: 164
USD 4900.00
(Single User License)
Global Omalizumab Biosimilars Market Research Report 2026
The global Omalizumab Biosimilars market was valued at US$ 290 million in 2025 and is anticipated to reach US$ 598 million by 2032, at a CAGR of 11.2% from 2026 to 2032.
Published Date: 2026-04-16
Pages: 120
USD 2900.00
(Single User License)
Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Omalizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 119
USD 3950.00
(Single User License)
Global Omalizumab Biosimilars Market Research Report 2025
The global market for Omalizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-01-16
Pages: 90
USD 2900.00
(Single User License)
Global Omalizumab Biosimilars Market Research Report 2024
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published Date: 2024-01-20
Pages: 90
USD 2900.00
(Single User License)
Omalizumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published Date: 2024-01-11
Pages: 122
USD 3950.00
(Single User License)

Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Omalizumab Biosimilars was estimated to be worth US$ 290 million in 2025 and is projected to reach US$ 598 million, growing at a CAGR of 11.2% from 2026 to 2032.
Published: 2026-04-16
Pages: 139
USD 3950.00 (Single User License)
Global Omalizumab Biosimilars Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Omalizumab Biosimilars market is projected to grow from US$ 290 million in 2025 to US$ 598 million by 2032, at a CAGR of 11.2% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-04-16
Pages: 164
USD 4900.00 (Single User License)
Global Omalizumab Biosimilars Market Research Report 2026
The global Omalizumab Biosimilars market was valued at US$ 290 million in 2025 and is anticipated to reach US$ 598 million by 2032, at a CAGR of 11.2% from 2026 to 2032.
Published: 2026-04-16
Pages: 120
USD 2900.00 (Single User License)
Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Omalizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 119
USD 3950.00 (Single User License)
Global Omalizumab Biosimilars Market Research Report 2025
The global market for Omalizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-01-16
Pages: 90
USD 2900.00 (Single User License)
Global Omalizumab Biosimilars Market Research Report 2024
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published: 2024-01-20
Pages: 90
USD 2900.00 (Single User License)
Omalizumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published: 2024-01-11
Pages: 122
USD 3950.00 (Single User License)